These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35670970)

  • 81. Significance of multifocality in papillary thyroid carcinoma.
    Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Selective sentinel lymph node biopsy in papillary thyroid carcinoma in patients with no preoperative evidence of lymph node metastasis.
    González Ó; Zafon C; Caubet E; García-Burillo A; Serres X; Fort JM; Mesa J; Castell J; Roca I; Ramón Y Cajal S; Iglesias C
    Endocrinol Diabetes Nutr; 2017 Oct; 64(8):451-455. PubMed ID: 28895542
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Application of Strict Criteria for Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Encapsulated Follicular Variant Papillary Thyroid Carcinoma: a Retrospective Study of 50 Tumors Previously Diagnosed as Follicular Variant PTC.
    Point du Jour K; du Jour KP; Schmitt AC; Chen AY; Griffith CC
    Endocr Pathol; 2018 Mar; 29(1):35-42. PubMed ID: 29368294
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Biotinidase is a novel marker for papillary thyroid cancer aggressiveness.
    So AK; Kaur J; Kak I; Assi J; MacMillan C; Ralhan R; Walfish PG
    PLoS One; 2012; 7(7):e40956. PubMed ID: 22911723
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Bilaterality weighs more than unilateral multifocality in predicting prognosis in papillary thyroid cancer.
    Qu N; Zhang L; Wu WL; Ji QH; Lu ZW; Zhu YX; Lin DZ
    Tumour Biol; 2016 Jul; 37(7):8783-9. PubMed ID: 26743781
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management.
    Xu B; Ghossein R
    Eur J Surg Oncol; 2018 Mar; 44(3):338-347. PubMed ID: 28554832
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Influence of Body Mass Index on the Clinicopathologic Features of Papillary Thyroid Carcinoma.
    Feng JW; Yang XH; Wu BQ; Sun DL; Jiang Y; Qu Z
    Ann Otol Rhinol Laryngol; 2019 Jul; 128(7):625-632. PubMed ID: 30841713
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.
    Fang Z; Song R; Gong C; Zhang X; Ren G; Li J; Chen Y; Qiu L; Mei L; Zhang R; Xiang X; Chen X; Shao J
    Tumour Biol; 2016 Mar; 37(3):3515-26. PubMed ID: 26453115
    [TBL] [Abstract][Full Text] [Related]  

  • 89. E-selectin expression and BRAF status in papillary thyroid carcinomas: Correlation with clinicopathologic features.
    Miccoli P; Torregrossa L; Borrelli N; Materazzi G; Cacciato Insilla A; Miccoli M; Basolo F
    Surgery; 2014 Dec; 156(6):1550-7; discussion 1557-8. PubMed ID: 25456953
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Extrathyroidal extension predicts negative clinical outcomes in papillary thyroid cancer.
    Bortz MD; Kuchta K; Winchester DJ; Prinz RA; Moo-Young TA
    Surgery; 2021 Jan; 169(1):2-6. PubMed ID: 32682508
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
    Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
    Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Pattern and Predictive Factors of Metastasis in Lymph Nodes Posterior to the Right Recurrent Laryngeal Nerve in Papillary Thyroid Carcinoma.
    Zhou M; Duan Y; Ye B; Wang Y; Li H; Wu Y; Chen P; Zhu J; Jing C; Wu Y; Wang X
    Front Endocrinol (Lausanne); 2022; 13():914946. PubMed ID: 35923627
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Significance of biologic aggressiveness and proliferating activity in papillary thyroid carcinoma.
    Kurozumi K; Nakao K; Nishida T; Nakahara M; Ogino N; Tsujimoto M
    World J Surg; 1998 Dec; 22(12):1237-42. PubMed ID: 9841750
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Papillary Thyroid Carcinoma in Ukraine After Chernobyl and in Japan After Fukushima: Different Histopathological Scenarios.
    Bogdanova TI; Saenko VA; Hashimoto Y; Hirokawa M; Zurnadzhy LY; Hayashi T; Ito M; Iwadate M; Mitsutake N; Rogounovitch TI; Sakamoto A; Naganuma H; Miyauchi A; Tronko MD; Thomas G; Yamashita S; Suzuki S
    Thyroid; 2021 Sep; 31(9):1322-1334. PubMed ID: 33143557
    [No Abstract]   [Full Text] [Related]  

  • 95. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Postsurgical pathology reporting of thyroid cancer in New South Wales, Australia.
    Kahn C; Simonella L; Sywak M; Boyages S; Ung O; O'Connell D
    Thyroid; 2012 Jun; 22(6):604-10. PubMed ID: 22524497
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The effect of surgeon experience on the detection of metastatic lymph nodes in the central compartment and the pathologic features of clinically unapparent metastatic lymph nodes: what are we missing when we don't perform a prophylactic dissection of central compartment lymph nodes in papillary thyroid cancer?
    Scherl S; Mehra S; Clain J; Dos Reis LL; Persky M; Turk A; Wenig B; Husaini H; Urken ML
    Thyroid; 2014 Aug; 24(8):1282-8. PubMed ID: 24787362
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence.
    Huang BY; Hseuh C; Chao TC; Lin KJ; Lin JD
    Endocr Pathol; 2011 Sep; 22(3):144-9. PubMed ID: 21647844
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.
    Liu C; Chen T; Liu Z
    World J Surg Oncol; 2016 Sep; 14(1):241. PubMed ID: 27600854
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Histological evaluation of thyroid carcinomas: reproducibility of the "WHO" classification.
    Fassina AS; Montesco MC; Ninfo V; Denti P; Masarotto G
    Tumori; 1993 Oct; 79(5):314-20. PubMed ID: 8116073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.